OncoMatch/Clinical Trials/NCT07052214
PSMA PET Combined With MRI for the Detection of PCa
Is NCT07052214 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies 68Ga-PSMA-11 for pca.
Treatment: 68Ga-PSMA-11 — This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Allowed: BRCA1 mutation
Allowed: BRCA2 mutation
Allowed: HOXB13 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any treatment for prostate cancer
Has had prior treatment for PCa or prior diagnosis of csPCa
Cannot have received: pelvic irradiation
Prior pelvic irradiation
Cannot have received: radionuclides
Exception: interval of less than 10 effective half-lives before the administration of 68Ga-PSMA-11
Have prior use of radionuclides with an interval of less than 10 effective half-lives before the administration of 68Ga-PSMA-11
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify